CIK 0001737287 · Non-accelerated filer<br>Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 823562771
- Phone
- (650) 457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $111,656
- in 2 filings
Net −$111,656. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 47 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-25 | Douglas Earl Martin SVP, General Counsel | Grant or award · Stock Option (Right to buy) | +147,778 | 147,778 | ||
| 2024-01-25 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award | +29,400 | 819,400 | ||
| 2024-01-25 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to buy) | +103,939 | 103,939 | ||
| 2024-01-25 | Belldegrun Arie Director | Grant or award | +211,973 | 1,866,859 | ||
| 2024-01-25 | Belldegrun Arie Director | Grant or award · Stock Option (Right to buy) | +749,398 | 749,398 | ||
| 2024-01-25 | Roberts Zachary EVP of R&D | Grant or award | +140,000 | 515,253 | ||
| 2024-01-25 | Roberts Zachary EVP of R&D | Grant or award · Stock Option (Right to buy) | +494,949 | 494,949 | ||
| 2024-01-25 | Chang David D President and CEO | Grant or award | +317,800 | 4,513,203 | ||
| 2024-01-25 | Chang David D President and CEO | Grant or award · Stock Option (Right to buy) | +1,123,535 | 1,123,535 | ||
| 2024-01-22 | Roberts Zachary EVP of R&D | Shares withheld for taxes | −24,690 | $3.17 | $78K | 375,253 |
| 2023-12-18 | MESSEMER DEBORAH M. Director | Sale 10b5-1 | −18,640 | $2.70 | $50K | 62,456 |
| 2023-10-16 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award | +400,000 | 400,000 | ||
| 2023-10-16 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award | +390,000 | 790,000 | ||
| 2023-10-16 | Parker Geoffrey M. CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (Right to Buy) | +950,000 | 950,000 | ||
| 2023-08-14 | Douglas Earl Martin GENERAL COUNSEL | Grant or award | +108,958 | 108,958 | ||
| 2023-08-14 | Douglas Earl Martin GENERAL COUNSEL | Grant or award | +326,876 | 435,834 | ||
| 2023-08-14 | Douglas Earl Martin GENERAL COUNSEL | Grant or award · Stock Option (Right to Buy) | +960,854 | 960,854 | ||
| 2023-08-10 | CHEN YINLIN JACK SVP, Finance | Grant or award | +11,401 | 88,881 | ||
| 2023-08-10 | CHEN YINLIN JACK SVP, Finance | Grant or award · Stock Option (Right to Buy) | +39,160 | 39,160 | ||
| 2023-08-07 | Mayo Stephen Director | Sale | −10,000 | $4.29 | $43K | 25,328 |
Page 6 of 18 · 348 trades